← Back to Clinical Trials
Recruiting NCT06284343

NCT06284343 The Gynecological Cancer Associated Thrombosis (GynCAT) Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06284343
Status Recruiting
Phase
Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Condition Cancer-associated Thrombosis
Study Type OBSERVATIONAL
Enrollment 1,800 participants
Start Date 2024-04-15
Primary Completion 2026-09-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Anticoagulant

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,800 participants in total. It began in 2024-04-15 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment, aiming at development and validation of a Risk Assessment Model (RAM) for Venous Thromboembolism (VTE) in this specific population.

Eligibility Criteria

Inclusion Criteria: * Female sex; * Diagnosis of gynecologic neoplasm (ovarian, tubal, uterine, cervical, vaginal, vulvar neoplasm); * Planned new line of systemic antineoplastic treatment; * Age of 18 years or older; * Accordance of Informed Consent. Exclusion Criteria: * Pregnant or breastfeeding women; * Indication to receive therapeutic dose anticoagulant therapy (e.g., atrial fibrillation, mechanical heart valve); * Diagnosis of symptomatic VTE at the time of screening for enrollment.

Contact & Investigator

Central Contact

Roberto Pola, PhD; MD

✉ roberto.pola@policlinicogemelli.it

📞 +39 0630157075

Principal Investigator

Roberto Pola, PhD; MD

PRINCIPAL INVESTIGATOR

Agostino Gemelli University Polyclinic Foundation IRCCS

Frequently Asked Questions

Who can join the NCT06284343 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Cancer-associated Thrombosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06284343 currently recruiting?

Yes, NCT06284343 is actively recruiting participants. Contact the research team at roberto.pola@policlinicogemelli.it for enrollment information.

Where is the NCT06284343 trial being conducted?

This trial is being conducted at Rome, Italy.

Who is sponsoring the NCT06284343 clinical trial?

NCT06284343 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Roberto Pola, PhD; MD at Agostino Gemelli University Polyclinic Foundation IRCCS. The trial plans to enroll 1,800 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology